Compare Nike Inc (NKE) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Smith & Nephew plc — how do they compare? Nike Inc trades at $34.71 (market cap $51.60B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Nike Inc is far larger — about 4.6× Smith & Nephew plc's market cap, and Nike Inc pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Smith & Nephew plc for 121 Days on average.
| NKE | SNN | |
|---|---|---|
Market Cap | $51.60B | $11.10B |
Volume | 43,506,062 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $37.17 |
52-Week Low | $33.87 | $26.42 |
Typical Hold Time | 155 Days | 121 Days |
Enterprise Value | $54.30B | $14.13B |
Dividend Yield | 4.72% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $34.74, up 1.11% with bearish technical signals despite recent earnings beats. The company faces revenue pressure with FY2025 sales declining to $46.31B and net margin compressing to 6.74%. Analyst consensus remains positive with a $36.98 price target, though technical indicators show 16 sell signals against 2 buy signals. Recent news highlights challenges in China and EMEA markets while emphasizing Nike's strong brand positioning.
Nike's investment case balances strong brand equity against near-term operational headwinds. The stock offers value at 16.62 P/E with 21.56% ROE, but investors face risks from sluggish consumer demand and margin pressure. The upcoming Q4 2026 earnings on June 30 will be critical for confirming turnaround progress.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
